usedtobeperkytina
Senior Member
- Messages
- 1,479
- Location
- Clay, Alabama
I was scared but optimistic. I know a government agency doesn't take a different path without a "committee" to study it and give recommendation. They have to back up what they do when asked. In such committees, though, you can tell the way it's likely going to go by who they invite to sit on the committee or to speak to the committee. Congressional committees are like that. So, after the workshop, my fear went down. I knew it would reflect advancement. I also noticed all they selected for the panel were women. I noticed one has history with lupus, a disease that is also invisible and hard to diagnose. They had a leader of a pain association, and we all know chronic pain is also dismissed with patients not believed. In fact, I wondered if any of them might know someone with ME/CFS. I notice the chair of the panel deals with public health to underserved people. So she would know about stigma.
I did not expect the AHRQ panel to advise discontinuing Oxford. To be honest, that surprised me in the workshop. But because of what was said during the workshop, I'm not surprised it's in this report. I'm surprised they addressed clinical care and educating physicians. Also mentioned bringing in more institutes, collaborating with medical professional organizations and finding a home for it. (I don't know if the last is referring to a home in NIH or specialty home for clinical care. Either way, it's good.) I'm surprised all these are mentioned because I don't think it's on point to research gaps, what they were charged to report on. These issues are more about clinical care.
But no one has mentioned the big surprise to me: The report says again and again that patient views and patient involvement should be included in all future research plans, by government agencies and individual researchers. This is not standard. Imagine if all ME/CFS researchers included three patients to advise and become coauthors on ME/CFS studies.
I did not expect the AHRQ panel to advise discontinuing Oxford. To be honest, that surprised me in the workshop. But because of what was said during the workshop, I'm not surprised it's in this report. I'm surprised they addressed clinical care and educating physicians. Also mentioned bringing in more institutes, collaborating with medical professional organizations and finding a home for it. (I don't know if the last is referring to a home in NIH or specialty home for clinical care. Either way, it's good.) I'm surprised all these are mentioned because I don't think it's on point to research gaps, what they were charged to report on. These issues are more about clinical care.
But no one has mentioned the big surprise to me: The report says again and again that patient views and patient involvement should be included in all future research plans, by government agencies and individual researchers. This is not standard. Imagine if all ME/CFS researchers included three patients to advise and become coauthors on ME/CFS studies.